Posts Tagged: op-eds

Dr. Raphael Hofstein in Biotechnology Focus: It’s time to declare an end to Canada’s two research solitudes

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by Dr. Raphael Hofstein, MaRS Innovation's president & CEO, and Elizabeth Monier-Williams, director of marketing and communications. The article explores the way research focused on discovery and commercialization are often viewed or positioned as competitors within the funding ecosystem and the need to align their goals: The time of Canada’s French and English solitudes may be past, as Governor General Michaëlle Jean notably stated when she took office ... Read more

Dr. Raphael Hofstein in Biotechnology Focus: Building a catalytic reaction across Canada’s Life Sciences Sector

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Raphael Hofstein. The article explores the role of catalysis in building Canada's Life Sciences sector: In chemistry, according to Encyclopædia Britannica Online, a catalyst is any substance that increases a reaction’s rate without itself being consumed. Kinetically, Wikipedia tells us, catalytic reactions are typical chemical reactions where the reaction rate depends on the reactants’ frequency of contact in the rate-determining step. Usually, ... Read more

VP Joel Liederman’s Financial Post article on mitigating innovation risk

MaRS Innovation's Vice-President of Business Development and Physical Sciences Joel Liederman, has published an article in the Financial Post about strategies to mitigate risk within the innovation space. The article, titled "Innovation Success Means Mitigating Risk," is featured in the newspaper's Productive Conversations section. (more…) Read more